-
Review Article
Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
- Luisa Gracio Ferreira Sartori
, - Bruno Monteiro Nunes ,
- Daniela Farah ,
- Leticia Maria de Oliveira ,
- Claudia Cristina Takano Novoa , [ ... ],
- Marcelo Cunio Machado Fonseca
08-04-2023
Summary
Review ArticleMirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
Revista Brasileira de Ginecologia e Obstetrícia. 2023;45(6):337-346
08-04-2023- Luisa Gracio Ferreira Sartori ,
- Bruno Monteiro Nunes ,
- Daniela Farah ,
- Leticia Maria de Oliveira ,
- Claudia Cristina Takano Novoa ,
- Marair Gracio Ferreira Sartori ,
- Marcelo Cunio Machado Fonseca
Views242See moreAbstract
Objective
To compare the use of mirabegron with anticholinergics drugs for the treatment of overactive bladder (OB).
Data Source
Systematic searches were conducted in EMBASE, PUBMED, Cochrane, and LILACS databases from inception to September 2021. We included RCTs, women with clinically proven OB symptoms, studies that compared mirabegron to antimuscarinic drugs, and that evaluated the efficacy, safety or adherence.
Data Collection
RevMan 5.4 was used to combine results across studies. We derived risk ratios (RRs) and mean differences with 95% CIs using a random-effects meta-analytic model. Cochrane Collaboration Tool and GRADE was applied for risk of bias and quality of the evidence.
Data Synthesis
We included 14 studies with a total of 10,774 patients. Fewer total adverse events was reported in mirabegron group than in antimuscarinics group [RR 0.93 (0.89–0.98)]. The risk of gastrointestinal tract disorders and dry mouth were lower with mirabegron [RR 0,58 (0.48–0.68); 9375 patients; RR 0.44 (0.35–0.56), 9375 patients, respectively]. No difference was reported between mirabegron and antimuscarinics drugs for efficacy. The adherence to treatment was 87.7% in both groups [RR 0.99 (0.98–1.00)].
Conclusion
Mirabegron and antimuscarinics have comparable efficacy and adherence rates; however, mirabegron showed fewer total and isolated adverse events.
Views242
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Summary
Review ArticleMirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
Revista Brasileira de Ginecologia e Obstetrícia. 2023;45(6):337-346
08-04-2023- Luisa Gracio Ferreira Sartori ,
- Bruno Monteiro Nunes ,
- Daniela Farah ,
- Leticia Maria de Oliveira ,
- Claudia Cristina Takano Novoa ,
- Marair Gracio Ferreira Sartori ,
- Marcelo Cunio Machado Fonseca
Views242See moreAbstract
Objective
To compare the use of mirabegron with anticholinergics drugs for the treatment of overactive bladder (OB).
Data Source
Systematic searches were conducted in EMBASE, PUBMED, Cochrane, and LILACS databases from inception to September 2021. We included RCTs, women with clinically proven OB symptoms, studies that compared mirabegron to antimuscarinic drugs, and that evaluated the efficacy, safety or adherence.
Data Collection
RevMan 5.4 was used to combine results across studies. We derived risk ratios (RRs) and mean differences with 95% CIs using a random-effects meta-analytic model. Cochrane Collaboration Tool and GRADE was applied for risk of bias and quality of the evidence.
Data Synthesis
We included 14 studies with a total of 10,774 patients. Fewer total adverse events was reported in mirabegron group than in antimuscarinics group [RR 0.93 (0.89–0.98)]. The risk of gastrointestinal tract disorders and dry mouth were lower with mirabegron [RR 0,58 (0.48–0.68); 9375 patients; RR 0.44 (0.35–0.56), 9375 patients, respectively]. No difference was reported between mirabegron and antimuscarinics drugs for efficacy. The adherence to treatment was 87.7% in both groups [RR 0.99 (0.98–1.00)].
Conclusion
Mirabegron and antimuscarinics have comparable efficacy and adherence rates; however, mirabegron showed fewer total and isolated adverse events.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. - Luisa Gracio Ferreira Sartori
mirabegron Archives - Revista Brasileira de Ginecologia e Obstetrícia
